[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CL2013000732A1 - Compuestos derivados de analogos de buprenorfina, con actividad como agonistas y/o antagonistas de receptores opioides; composicion que los comprende; su metodo de preparacion; y su uso para el tratamiento o prevencion del dolor o constipacion. - Google Patents

Compuestos derivados de analogos de buprenorfina, con actividad como agonistas y/o antagonistas de receptores opioides; composicion que los comprende; su metodo de preparacion; y su uso para el tratamiento o prevencion del dolor o constipacion.

Info

Publication number
CL2013000732A1
CL2013000732A1 CL2013000732A CL2013000732A CL2013000732A1 CL 2013000732 A1 CL2013000732 A1 CL 2013000732A1 CL 2013000732 A CL2013000732 A CL 2013000732A CL 2013000732 A CL2013000732 A CL 2013000732A CL 2013000732 A1 CL2013000732 A1 CL 2013000732A1
Authority
CL
Chile
Prior art keywords
constipation
agonists
pain
prevention
activity
Prior art date
Application number
CL2013000732A
Other languages
English (en)
Inventor
Donald J Kyle
Laykea Tafesse
Original Assignee
Purdue Pharma Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44903285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013000732(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Purdue Pharma Lp filed Critical Purdue Pharma Lp
Publication of CL2013000732A1 publication Critical patent/CL2013000732A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compuestos derivados de análogos de buprenorfina, con actividad como agonistas y/o antagonistas de receptores opioides; composición que los comprende; su método de preparación; y su uso para el tratamiento o prevención del dolor o constipación.
CL2013000732A 2010-09-21 2013-03-18 Compuestos derivados de analogos de buprenorfina, con actividad como agonistas y/o antagonistas de receptores opioides; composicion que los comprende; su metodo de preparacion; y su uso para el tratamiento o prevencion del dolor o constipacion. CL2013000732A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38491210P 2010-09-21 2010-09-21
US201161503674P 2011-07-01 2011-07-01

Publications (1)

Publication Number Publication Date
CL2013000732A1 true CL2013000732A1 (es) 2013-07-26

Family

ID=44903285

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013000732A CL2013000732A1 (es) 2010-09-21 2013-03-18 Compuestos derivados de analogos de buprenorfina, con actividad como agonistas y/o antagonistas de receptores opioides; composicion que los comprende; su metodo de preparacion; y su uso para el tratamiento o prevencion del dolor o constipacion.

Country Status (34)

Country Link
US (1) US9221831B2 (es)
EP (1) EP2619212B1 (es)
JP (2) JP5977240B2 (es)
KR (2) KR20150027315A (es)
CN (2) CN105399751A (es)
AR (1) AR083062A1 (es)
AU (1) AU2011306644B2 (es)
CA (1) CA2810356C (es)
CL (1) CL2013000732A1 (es)
CO (1) CO6690803A2 (es)
CR (1) CR20130129A (es)
CY (1) CY1117227T1 (es)
DK (1) DK2619212T3 (es)
DO (1) DOP2013000060A (es)
EA (1) EA201390422A1 (es)
EC (1) ECSP13012543A (es)
ES (1) ES2566828T3 (es)
HK (1) HK1187045A1 (es)
HR (1) HRP20160281T1 (es)
HU (1) HUE027195T2 (es)
ME (1) ME02367B (es)
MX (1) MX2013003354A (es)
NI (1) NI201300032A (es)
NZ (1) NZ609200A (es)
PE (1) PE20140020A1 (es)
PL (1) PL2619212T3 (es)
RS (1) RS54579B1 (es)
SG (1) SG188300A1 (es)
SI (1) SI2619212T1 (es)
SM (1) SMT201600088B (es)
TW (2) TW201242968A (es)
UY (1) UY33618A (es)
WO (1) WO2012038813A1 (es)
ZA (1) ZA201301217B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
NZ597621A (en) 2007-05-25 2013-06-28 Tolmar Therapeutics Inc Sustained delivery formulations of risperidone compounds
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
EP2582366B1 (en) 2010-06-15 2015-10-28 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
MX361350B (es) 2011-05-10 2018-12-04 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal de sodio.
TWI622583B (zh) 2011-07-01 2018-05-01 基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (es) 2011-07-01 2018-04-28
WO2013084060A1 (en) 2011-12-08 2013-06-13 Purdue Pharma L.P. Quaternized buprenorphine analogs
US9315514B2 (en) * 2012-08-27 2016-04-19 Rhodes Technologies 1,3-dioxanomorphides and 1,3-dioxanocodides
US10138207B2 (en) 2012-11-09 2018-11-27 Purdue Pharma, L.P. Benzomorphan analogs and the use thereof
EP2931729B1 (en) 2012-12-07 2019-02-06 Purdue Pharma LP Buprenorphine analogs as opiod receptor modulators
CA2900023A1 (en) 2013-01-31 2014-08-07 Purdue Pharma L.P. Benzomorphan analogs and the use thereof
US8969358B2 (en) 2013-03-15 2015-03-03 Purdue Pharma L.P. Buprenorphine analogs
US9994571B2 (en) 2013-12-26 2018-06-12 Purdue Pharma L.P. 10-substituted morphinan hydantoins
JP6353543B2 (ja) 2013-12-26 2018-07-04 パーデュー、ファーマ、リミテッド、パートナーシップ 環縮小モルフィナン及びその使用
EP3087078B1 (en) * 2013-12-26 2019-05-15 Purdue Pharma LP 7-beta-alkyl analogs of orvinols
US20160333020A1 (en) * 2013-12-26 2016-11-17 Purdue Pharma L.P. 7-beta analogs of orvinols
US9862726B2 (en) 2013-12-26 2018-01-09 Purdue Pharma L.P. Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
WO2015099863A1 (en) 2013-12-27 2015-07-02 Purdue Pharma L.P. 6-substituted and 7-substituted morphinan analogs and the use thereof
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
CA2950567A1 (en) 2014-05-27 2015-12-03 Purdue Pharma L.P. Spirocyclic morphinans and use thereof
CA2951697A1 (en) 2014-06-13 2015-12-17 Purdue Pharma L.P. Azamophinan derivatives and use thereof
MA41125A (fr) 2014-12-05 2017-10-10 Purdue Pharma Lp Dérivés de 6.7-cyclomorphinane et leur utilisation
JP2018531955A (ja) * 2015-10-26 2018-11-01 オーフォームド，インコーポレイティド ブプレノルフィンのエチレングリコールエーテル
EP3390355B1 (en) * 2016-03-22 2022-12-28 Helsinn Healthcare S.A. Benzenesulfonyl-asymmetric ureas and medical uses thereof
WO2018125716A1 (en) 2017-01-02 2018-07-05 Purdue Pharma L.P. Morphinan derivatives and use thereof
EP3625235A1 (en) * 2017-05-19 2020-03-25 River Stone Biotech, LLC Preparation of buprenorphine
JP2021104932A (ja) * 2018-03-30 2021-07-26 日本ケミファ株式会社 モルヒナン誘導体の製造方法
WO2024044179A1 (en) * 2022-08-23 2024-02-29 Virginia Commonwealth University Multiple targeting opioid receptor ligands as novel analgesics with minimum abuse liability

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1136764A (en) * 1965-08-13 1968-12-18 Reckitt & Sons Ltd Derivatives of thebaine and oripavine
AU732329B2 (en) 1997-05-30 2001-04-12 Banyu Pharmaceutical Co., Ltd. 2-oxoimidazole derivative
SK14272000A3 (sk) 1998-03-26 2001-05-10 Japan Tobacco Inc. Antagonista nociceptínu, derivát amidu, farmaceutický prostriedok, spôsob, použitie a komerčné balenie
IL157662A0 (en) 2001-03-02 2004-03-28 Euro Celtique Sa N-but-3-enyl norbuprenorphine and its use as analgesic
US6740641B2 (en) 2001-07-27 2004-05-25 Euro-Celtique, S.A. Sugar derivatives of hydromorphone, dihydromorphine and dihydromorphine, compositions thereof and uses for treating or preventing pain
ATE360633T1 (de) 2002-09-25 2007-05-15 Euro Celtique Sa N-substituierte hydromorphone und ihre anwendung
EP1554290B1 (en) 2002-10-25 2009-09-30 Euro-Celtique S.A. Analogs and prodrugs of buprenorphine
US7202259B2 (en) 2002-11-18 2007-04-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US6958398B1 (en) 2002-12-30 2005-10-25 Euro-Celtique S.A. Methods for making thebaine or its acid salts
KR20120031245A (ko) 2006-11-01 2012-03-30 퍼듀 퍼머 엘피 페닐프로피온아미드 화합물 및 그의 용도
GB2447014A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
US8426594B2 (en) 2007-11-30 2013-04-23 Purdue Pharma L.P. Benzomorphan compounds
PL2326651T3 (pl) * 2008-07-30 2014-05-30 Purdue Pharma Lp Analogi buprenorfiny
US9133131B2 (en) 2011-11-15 2015-09-15 Purdue Pharma L.P. Pyrimidine diol amides as sodium channel blockers
WO2013084060A1 (en) 2011-12-08 2013-06-13 Purdue Pharma L.P. Quaternized buprenorphine analogs
AR091027A1 (es) 2012-05-11 2014-12-30 Purdue Pharma Lp Analogos de benzomorfano y el usos de estos
US9315514B2 (en) 2012-08-27 2016-04-19 Rhodes Technologies 1,3-dioxanomorphides and 1,3-dioxanocodides
US10138207B2 (en) 2012-11-09 2018-11-27 Purdue Pharma, L.P. Benzomorphan analogs and the use thereof
EP2931729B1 (en) 2012-12-07 2019-02-06 Purdue Pharma LP Buprenorphine analogs as opiod receptor modulators
EP2931725B1 (en) 2012-12-14 2017-02-15 Purdue Pharma LP Nitrogen containing morphinan derivatives and the use thereof
WO2014091295A1 (en) 2012-12-14 2014-06-19 Purdue Pharma L.P. Pyridonemorphinan analogs and biological activity on opioid receptors
TW201434837A (zh) 2012-12-14 2014-09-16 Purdue Pharma Lp 螺環嗎啡喃及其用途
TW201441199A (zh) 2012-12-28 2014-11-01 Purdue Pharma Lp 經取代之嗎啡喃類及其用途
WO2014102587A1 (en) 2012-12-28 2014-07-03 Purdue Pharma L.P. 7,8-cyclicmorphinan analogs
CA2900023A1 (en) 2013-01-31 2014-08-07 Purdue Pharma L.P. Benzomorphan analogs and the use thereof
US8969358B2 (en) 2013-03-15 2015-03-03 Purdue Pharma L.P. Buprenorphine analogs
US20160333020A1 (en) 2013-12-26 2016-11-17 Purdue Pharma L.P. 7-beta analogs of orvinols
EP3087078B1 (en) 2013-12-26 2019-05-15 Purdue Pharma LP 7-beta-alkyl analogs of orvinols
US9994571B2 (en) 2013-12-26 2018-06-12 Purdue Pharma L.P. 10-substituted morphinan hydantoins
WO2015097546A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. Propellane-based compounds and their use as opioid receptor modulators
WO2015099863A1 (en) 2013-12-27 2015-07-02 Purdue Pharma L.P. 6-substituted and 7-substituted morphinan analogs and the use thereof
WO2015102682A1 (en) 2013-12-30 2015-07-09 Purdue Pharma L.P. Pyridone-sulfone morphinan analogs as opioid receptor ligands

Also Published As

Publication number Publication date
HUE027195T2 (en) 2016-10-28
AU2011306644A1 (en) 2013-04-11
DK2619212T3 (en) 2016-03-21
KR20150027315A (ko) 2015-03-11
JP2016102115A (ja) 2016-06-02
EA201390422A1 (ru) 2014-01-30
KR20130097210A (ko) 2013-09-02
JP5977240B2 (ja) 2016-08-24
ZA201301217B (en) 2013-09-25
SG188300A1 (en) 2013-04-30
SI2619212T1 (sl) 2016-04-29
JP2013543488A (ja) 2013-12-05
NI201300032A (es) 2014-01-13
CA2810356C (en) 2016-06-14
US20140057931A1 (en) 2014-02-27
RS54579B1 (en) 2016-06-30
UY33618A (es) 2012-03-30
KR101630912B1 (ko) 2016-06-15
MX2013003354A (es) 2013-06-24
CO6690803A2 (es) 2013-06-17
SMT201600088B (it) 2016-04-29
TW201422621A (zh) 2014-06-16
DOP2013000060A (es) 2013-04-30
AU2011306644B2 (en) 2015-07-02
ME02367B (me) 2016-06-20
CY1117227T1 (el) 2017-04-05
EP2619212B1 (en) 2016-01-06
EP2619212A1 (en) 2013-07-31
CR20130129A (es) 2013-08-29
ES2566828T3 (es) 2016-04-15
TW201242968A (en) 2012-11-01
PE20140020A1 (es) 2014-01-31
CN103154000A (zh) 2013-06-12
WO2012038813A1 (en) 2012-03-29
PL2619212T3 (pl) 2016-09-30
ECSP13012543A (es) 2013-06-28
HRP20160281T1 (hr) 2016-04-08
CA2810356A1 (en) 2012-03-29
US9221831B2 (en) 2015-12-29
NZ609200A (en) 2015-01-30
CN105399751A (zh) 2016-03-16
HK1187045A1 (en) 2014-03-28
AR083062A1 (es) 2013-01-30

Similar Documents

Publication Publication Date Title
CL2013000732A1 (es) Compuestos derivados de analogos de buprenorfina, con actividad como agonistas y/o antagonistas de receptores opioides; composicion que los comprende; su metodo de preparacion; y su uso para el tratamiento o prevencion del dolor o constipacion.
CL2015003290A1 (es) Nuevos agonistas del receptor de somatostatina subtipo 4 (sstr4).
CR20150296A (es) Novedosos derivados de bencimidazol como antagonistas de ep4
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
UY32327A (es) Antagonistas de receptores de ácido lisofosfatídico
CL2013001677A1 (es) Compuestos derivados de azabiciclo[3.2.1]octano; agonista del receptor x fernesoide (fxr); proceso para preparar los compuestos; compuesto intermediario; composicion farmaceutica y combinacion farmaceutica que comporenden un compuesto; y uso de los compuestos en la preparacion de medicamentos para el tratamiento de dislipidemia.
CO6400170A2 (es) Agosnistas y antagonistas del receptor s1p5 y métodos de uso de los mismos
CO7400870A2 (es) Compuestos derivadios de quinuclidina con actividad antagonista de los receptores muscarínicos y actividad agonista del receptor beta2 adrenérgico
ECSP12012270A (es) Compuestos de pirazol como inhibidores del receptor sigma
MY163055A (en) Polycyclic antagonists of lysophosphatidic acid receptors
CL2012003745A1 (es) Compuestos derivados de aminopirazoloquinazolinas, como inhibidores frente a la actividad fosforilante del receptor igf-1 localizado en membranas celulares; preparacion farmaceutica que los contiene; y su uso en el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
CL2017002017A1 (es) Compuestos con actividad antagonista de los receptoresmuscarínicos y actividad agonista del receptor beta2 adrenérgico
ECSP13012519A (es) Compuestos sustituidos de benzamida
CL2015002202A1 (es) Benzamidas sustituidas con actividad hacia receptores ep4.
NI201400042A (es) 2 - tiopirimidinonas
UY32734A (es) Compuestos agonistas del receptor esfingosina 1-fosfato
BR112015012720A2 (pt) derivados de feniletilpiridina como inibidores de pde4
UY35906A (es) Novedosos derivados de bencimidazol como ligandos de ep4
CR20140257A (es) Nuevos 2h-indazoles como antagonistas del receptor ep2
MX2017005484A (es) Compuestos antagonistas del receptor de dopamina d3.
MX2015011536A (es) Nuevos antagonistas de receptores trpa1 de sulfamidas.
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.
MX2017015047A (es) Compuestos que tienen actividad antagonista del receptor muscarinico y actividad agonista del receptor beta2 adrenergico.
CL2012003253A1 (es) Compuestos derivados de 1,3,4-tiadiazol alquilamidas y de chalconas, antagonistas del receptor trpv-1; uso de los compuestos para tratar el dolor cronico.